Skip to main content
Jeffrey Jones, MD, Oncology, Cambridge, MA

Jeffrey A. Jones MD MPH MBA

Hematologic Oncology


Chief Medical Officer Cullinan Oncology

Join to View Full Profile
  • 1 Main Street Suite 520Cambridge, MA 02142

Dr. Jones is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Ohio State University Fisher College of Business
    Ohio State University Fisher College of BusinessMBA, 2015 - 2017
  • University of Texas School of Public Health
    University of Texas School of Public HealthMPH, 2004 - 2006
  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 2000

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2018 - 2025
  • NJ State Medical License
    NJ State Medical License 2017 - 2023
  • OH State Medical License
    OH State Medical License 2006 - 2018

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

Journal Articles

  • Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical Trials  
    Steven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
  • Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia  
    Jeffrey A Jones, William Wierda, Clinical Cancer Research

Press Mentions

  • Shop Talk
    Shop TalkNovember 25th, 2017
  • Idelalisib Use Expands with New CLL Indication Pending
    Idelalisib Use Expands with New CLL Indication PendingJuly 30th, 2015
  • REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
    REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsAugust 6th, 2023

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: